GB201717260D0 - Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Info

Publication number
GB201717260D0
GB201717260D0 GBGB1717260.2A GB201717260A GB201717260D0 GB 201717260 D0 GB201717260 D0 GB 201717260D0 GB 201717260 A GB201717260 A GB 201717260A GB 201717260 D0 GB201717260 D0 GB 201717260D0
Authority
GB
United Kingdom
Prior art keywords
treatment
novel compounds
inflammatory disorders
ceutical compositions
pharma ceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1717260.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to GBGB1717260.2A priority Critical patent/GB201717260D0/en
Publication of GB201717260D0 publication Critical patent/GB201717260D0/en
Priority to CN202311478101.5A priority patent/CN117534670A/zh
Priority to EP18788711.2A priority patent/EP3697784B9/en
Priority to PCT/EP2018/077677 priority patent/WO2019076716A1/en
Priority to LTEPPCT/EP2018/077677T priority patent/LT3697784T/lt
Priority to KR1020207014284A priority patent/KR20200074178A/ko
Priority to HUE18788711A priority patent/HUE063998T2/hu
Priority to US16/757,189 priority patent/US11564923B2/en
Priority to AU2018350592A priority patent/AU2018350592B2/en
Priority to RS20231045A priority patent/RS64800B1/sr
Priority to PT187887112T priority patent/PT3697784T/pt
Priority to BR112020007541-8A priority patent/BR112020007541A2/pt
Priority to IL273943A priority patent/IL273943B2/en
Priority to CA3079449A priority patent/CA3079449A1/en
Priority to CN201880067863.7A priority patent/CN111225916B/zh
Priority to MX2020003863A priority patent/MX2020003863A/es
Priority to DK18788711.2T priority patent/DK3697784T5/da
Priority to MA50391A priority patent/MA50391B1/fr
Priority to FIEP18788711.2T priority patent/FI3697784T5/fi
Priority to SG11202003516TA priority patent/SG11202003516TA/en
Priority to RU2020116376A priority patent/RU2785126C2/ru
Priority to ES18788711T priority patent/ES2967432T3/es
Priority to PL18788711.2T priority patent/PL3697784T3/pl
Priority to EP23191626.3A priority patent/EP4265254A3/en
Priority to SI201831002T priority patent/SI3697784T1/sl
Priority to HRP20231315TT priority patent/HRP20231315T1/hr
Priority to IL302615A priority patent/IL302615A/en
Priority to JP2020521991A priority patent/JP7292271B2/ja
Priority to ARP180103068A priority patent/AR113784A1/es
Priority to TW107136998A priority patent/TWI805629B/zh
Priority to PH12020550230A priority patent/PH12020550230A1/en
Priority to CONC2020/0005200A priority patent/CO2020005200A2/es
Priority to ZA2020/02166A priority patent/ZA202002166B/en
Priority to US18/146,698 priority patent/US20230310433A1/en
Priority to AU2023201522A priority patent/AU2023201522A1/en
Priority to JP2023093474A priority patent/JP2023113834A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB1717260.2A 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders Ceased GB201717260D0 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
JP2020521991A JP7292271B2 (ja) 2017-10-20 2018-10-11 炎症性障害の治療のための新規化合物及びその医薬組成物
DK18788711.2T DK3697784T5 (da) 2017-10-20 2018-10-11 Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser
SG11202003516TA SG11202003516TA (en) 2017-10-20 2018-10-11 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA50391A MA50391B1 (fr) 2017-10-20 2018-10-11 Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
EP18788711.2A EP3697784B9 (en) 2017-10-20 2018-10-11 Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
KR1020207014284A KR20200074178A (ko) 2017-10-20 2018-10-11 염증 질환의 치료를 위한 신규 화합물 및 그의 약학 조성물
HUE18788711A HUE063998T2 (hu) 2017-10-20 2018-10-11 Imidazo[4,5-b]piridin vegyületek és azok gyógyászati készítményei gyulladásos betegségek kezelésére
US16/757,189 US11564923B2 (en) 2017-10-20 2018-10-11 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2018350592A AU2018350592B2 (en) 2017-10-20 2018-10-11 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
RS20231045A RS64800B1 (sr) 2017-10-20 2018-10-11 Imidazo[4,5-b]piridinska jedinjenja i njihove farmaceutske kompozicije za lečenje inflamatornih poremećaja
PT187887112T PT3697784T (pt) 2017-10-20 2018-10-11 Compostos de imidazo[4,5-b]piridina e respectivas composições farmacêuticas para o tratamento de doenças inflamatórias
BR112020007541-8A BR112020007541A2 (pt) 2017-10-20 2018-10-11 compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
IL273943A IL273943B2 (en) 2017-10-20 2018-10-11 New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
CA3079449A CA3079449A1 (en) 2017-10-20 2018-10-11 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN201880067863.7A CN111225916B (zh) 2017-10-20 2018-10-11 用于治疗炎性障碍的新化合物及其药物组合物
MX2020003863A MX2020003863A (es) 2017-10-20 2018-10-11 Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
CN202311478101.5A CN117534670A (zh) 2017-10-20 2018-10-11 用于治疗炎性障碍的新化合物及其药物组合物
PCT/EP2018/077677 WO2019076716A1 (en) 2017-10-20 2018-10-11 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS RELATED THERETO FOR THE TREATMENT OF INFLAMMATORY DISORDERS
LTEPPCT/EP2018/077677T LT3697784T (lt) 2017-10-20 2018-10-11 Imidazo[4,5-b]piridino junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui
FIEP18788711.2T FI3697784T5 (fi) 2017-10-20 2018-10-11 Imidatso[4,5-b]pyridiiniyhdisteet ja niiden farmaseuttiset koostu- mukset tulehduksellisten häiriöiden hoitoa varten
RU2020116376A RU2785126C2 (ru) 2017-10-20 2018-10-11 Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
ES18788711T ES2967432T3 (es) 2017-10-20 2018-10-11 Compuestos de imidazo[4,5-b]piridina y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
PL18788711.2T PL3697784T3 (pl) 2017-10-20 2018-10-11 Związki imidazo[4,5-b]pirydyny i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych
EP23191626.3A EP4265254A3 (en) 2017-10-20 2018-10-11 Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SI201831002T SI3697784T1 (sl) 2017-10-20 2018-10-11 Imidazo(4,5-B)piridinske spojine in farmacevtski sestavki iz teh za zdravljenje vnetnih motenj
HRP20231315TT HRP20231315T1 (hr) 2017-10-20 2018-10-11 Imidazo[4,5-b]piridinski spojevi i njihovi farmaceutski pripravci radi liječenja upalnih poremećaja
IL302615A IL302615A (en) 2017-10-20 2018-10-11 New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
TW107136998A TWI805629B (zh) 2017-10-20 2018-10-19 用於治療發炎性病症之新穎化合物及其醫藥組合物
ARP180103068A AR113784A1 (es) 2017-10-20 2018-10-19 Compuestos de imidazopiridina y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
PH12020550230A PH12020550230A1 (en) 2017-10-20 2020-04-07 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CONC2020/0005200A CO2020005200A2 (es) 2017-10-20 2020-04-27 Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios
ZA2020/02166A ZA202002166B (en) 2017-10-20 2020-05-04 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US18/146,698 US20230310433A1 (en) 2017-10-20 2022-12-27 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2023201522A AU2023201522A1 (en) 2017-10-20 2023-03-10 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2023093474A JP2023113834A (ja) 2017-10-20 2023-06-06 炎症性障害の治療のための新規化合物及びその医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1717260.2A GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
GB201717260D0 true GB201717260D0 (en) 2017-12-06

Family

ID=60481889

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1717260.2A Ceased GB201717260D0 (en) 2017-10-20 2017-10-20 Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Country Status (29)

Country Link
US (2) US11564923B2 (lt)
EP (2) EP4265254A3 (lt)
JP (2) JP7292271B2 (lt)
KR (1) KR20200074178A (lt)
CN (2) CN111225916B (lt)
AR (1) AR113784A1 (lt)
AU (2) AU2018350592B2 (lt)
BR (1) BR112020007541A2 (lt)
CA (1) CA3079449A1 (lt)
CO (1) CO2020005200A2 (lt)
DK (1) DK3697784T5 (lt)
ES (1) ES2967432T3 (lt)
FI (1) FI3697784T5 (lt)
GB (1) GB201717260D0 (lt)
HR (1) HRP20231315T1 (lt)
HU (1) HUE063998T2 (lt)
IL (2) IL273943B2 (lt)
LT (1) LT3697784T (lt)
MA (1) MA50391B1 (lt)
MX (1) MX2020003863A (lt)
PH (1) PH12020550230A1 (lt)
PL (1) PL3697784T3 (lt)
PT (1) PT3697784T (lt)
RS (1) RS64800B1 (lt)
SG (1) SG11202003516TA (lt)
SI (1) SI3697784T1 (lt)
TW (1) TWI805629B (lt)
WO (1) WO2019076716A1 (lt)
ZA (1) ZA202002166B (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
WO2020240586A1 (en) * 2019-05-28 2020-12-03 Mankind Pharma Ltd. Novel compounds for inhibition of janus kinase 1
IL309946A (en) 2021-07-12 2024-03-01 Galapagos Nv Treatment of inflammatory diseases
WO2023161327A1 (en) * 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases
WO2023161326A1 (en) 2022-02-24 2023-08-31 Galapagos Nv Compound for use in and methods of treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2809671B1 (en) * 2012-01-30 2016-01-13 Cephalon, Inc. Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (en) 2015-07-20 2017-01-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AR105400A1 (es) * 2015-08-04 2017-09-27 Lilly Co Eli Inhibidores de jak1
WO2018075937A1 (en) * 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
PT3697784T (pt) 2024-01-09
RU2020116376A (ru) 2021-11-22
IL273943B2 (en) 2023-10-01
CA3079449A1 (en) 2019-04-25
IL273943A (en) 2020-05-31
JP7292271B2 (ja) 2023-06-16
AU2018350592A1 (en) 2020-06-04
EP4265254A2 (en) 2023-10-25
WO2019076716A1 (en) 2019-04-25
HRP20231315T1 (hr) 2024-02-16
PL3697784T3 (pl) 2024-03-11
DK3697784T3 (da) 2023-10-30
CN111225916B (zh) 2023-11-03
EP3697784B9 (en) 2023-12-27
IL273943B1 (en) 2023-06-01
AU2023201522A1 (en) 2023-04-13
HUE063998T2 (hu) 2024-02-28
TWI805629B (zh) 2023-06-21
JP2020537672A (ja) 2020-12-24
MA50391A (fr) 2021-04-21
SI3697784T1 (sl) 2023-11-30
ZA202002166B (en) 2021-05-26
DK3697784T5 (da) 2024-01-15
JP2023113834A (ja) 2023-08-16
AU2018350592B2 (en) 2022-12-22
PH12020550230A1 (en) 2021-02-08
RU2020116376A3 (lt) 2021-11-22
EP3697784A1 (en) 2020-08-26
RS64800B1 (sr) 2023-11-30
CN117534670A (zh) 2024-02-09
US20230310433A1 (en) 2023-10-05
US11564923B2 (en) 2023-01-31
MX2020003863A (es) 2020-08-13
EP3697784B1 (en) 2023-10-04
EP4265254A3 (en) 2024-03-13
IL302615A (en) 2023-07-01
AR113784A1 (es) 2020-06-10
LT3697784T (lt) 2023-10-25
CO2020005200A2 (es) 2020-05-29
SG11202003516TA (en) 2020-05-28
BR112020007541A2 (pt) 2020-09-24
FI3697784T5 (fi) 2024-01-12
FI3697784T3 (fi) 2023-10-31
CN111225916A (zh) 2020-06-02
TW201918483A (zh) 2019-05-16
KR20200074178A (ko) 2020-06-24
ES2967432T3 (es) 2024-04-30
MA50391B1 (fr) 2023-11-30
US20210169879A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HK1249507A1 (zh) 用於治療炎性障礙的新化合物及其藥物組合物
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
GB201717260D0 (en) Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
GB201710851D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
GB201610056D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201610055D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
IL286677A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL286685A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201702604D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201718856D0 (en) Medicinal compositions for the treatment of inflammatory conditions and autoimmune diseases
GB201807222D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammation disorders
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
IL254140A0 (en) Preparations and combinations for use in the treatment of angiogenic diseases and disorders
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)